CTLA4 and non-small cell lung carcinoma: A recent retrospective study of two trials investigating either anti-PD1 or anti-CTLA4 agents given with SBRT for metastatic non-small cell lung cancer found that SBRT increased the efficacy of PD1 therapy by 98% relative to historical controls (31).